Variable | Total Sample | CKD Cohorts | Other Cohorts |
---|---|---|---|

N | 1,277,217 | 249,977 | 1,027,240 |

Median no. SCre (IQR) | 5 (4–5) | 7 (7–7) | 5 (4–5) |

Slope <−5 ml/yr | |||

N, % | 11 | 12 | 11 |

Age (SD), yr | 58 (17) | 73 (11) | 54 (17) |

Women, % | 49 | 9 | 60 |

Black, % | 4 | 15 | 1 |

Slope ≥−5 to ≤5 ml/yr | |||

N, % | 84 | 80 | 85 |

Age (SD), yr | 59 (17) | 76 (10) | 55 (16) |

Women, % | 48 | 9 | 56 |

Black, % | 2 | 9 | 0 |

Slope >5 ml/yr | |||

N, % | 5 | 7 | 4 |

Age (SD), yr | 57 (19) | 73 (10) | 50 (17) |

Women, % | 48 | 11 | 63 |

Black, % | 3 | 10 | 1 |

Mean (SD) follow-up,^{a} yr | 3.2 (4.0) | 3 (1) | 3 (4) |

ACM events | 102,477 | 57,269 | 45,208 |

CVM events^{b} | 8231 | 340 | 7891 |

Slope <−5 ml/yr is the declining eGFR group with an annualized eGFR slope of <−5 ml/min per 1.73 m

^{2}per year.*N*, % is the proportion of the cohort belonging to a given slope category. Slope ≥−5 to ≤5 ml/yr is the stable eGFR group with an annualized GFR between ≥−5 and ≤5 ml/min per 1.73 m^{2}per year. Slope >5 ml/yr is the increasing eGFR group with an annualized eGFR slope of >5 ml/min per 1.73 m^{2}per year. SCre, serum creatinine measurements available during the antecedent period; CVM, cardiovascular mortality.↵a Follow-up time refers to the at-risk period subsequent to the 3-year antecedent interval.

↵b Not all cohorts could provide data with respect to CVM (Supplemental Table 2).